公开(公告)号：US20230233671A1

公开(公告)日：2023-07-27

申请号：US18045967

申请日：2022-10-12

Applicant: Pfizer Inc.

Inventor： Eric Matthew Bennett ,  Fernando Martin Diaz ,  Philip Ralph Dormitzer ,  Kathrin Ute Jansen ,  Raquel Munoz-Moreno ,  Alicia Solorzano Quijano

IPC: A61K39/25 ,  A61K47/69 ,  A61K47/10 ,  A61K47/28 ,  A61P37/04

CPC classification number: A61K39/25 ,  A61K47/6929 ,  A61K47/10 ,  A61K47/28 ,  A61P37/04

Abstract: The present disclosure relates to RNA molecules encoding a varicella zoster virus (VZV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment or prevention of herpes zoster or shingles.

公开(公告)号：US20240209061A1

公开(公告)日：2024-06-27

申请号：US17908822

申请日：2021-03-05

Applicant: Pfizer Inc.

Inventor： Eric Matthew Bennett ,  Christina Hwei-Lin Eng ,  Laura Lin Lohse ,  Lidia Mosyak ,  Jeremy Shawn Myers ,  Mohosin Sarkar ,  Hayretin Rafet Yumerefendi

IPC: C07K14/705 ,  A61K31/5025 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K14/70532 ,  A61K31/5025 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/94 ,  C07K2319/30

Abstract: The present invention provides for CD80-Fc fusion proteins that have therapeutic and diagnostic use, and methods for making thereof. The present invention further relates to variant CD80 polypeptides. The present invention also provides for CD80-Fc fusion proteins for use in the treatment of cancer.

公开(公告)号：US20250000960A1

公开(公告)日：2025-01-02

申请号：US18739401

申请日：2024-06-11

Applicant: Pfizer Inc.

Inventor： Eric Matthew Bennett ,  Robert George Konrad Donald ,  Laura Lin Lohse ,  Natalie Clare Silmon de Monerri

IPC: A61K39/108 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K39/00 ,  A61P31/04 ,  C07K14/245 ,  C12N15/11

Abstract: The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.